Agranulocytosis and lupus erythematosus phenomenon after procaine amide.
D000380:Agranulocytosis / Q000139:chemically induced* / Q000150:complications*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D004342:Drug Hypersensitivity; D005492:Folic Acid / Q000627:therapeutic use; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced* / Q000150:complications*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D011342:Procainamide / Q000009:adverse effects*; D011802:Quinidine / Q000009:adverse effects
D000900:Anti-Bacterial Agents; D005492:Folic Acid; D011802:Quinidine; D011342:Procainamide; D011241:Prednisone